NX
NXGL.US Nexgel Inc
- Market cap
- USD 2.08M
- P/E
- -
- P/B
- 0.43x
- ROE
- -184.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NXGL.US undervalued?
Graham numberThe Graham number of Nexgel Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nexgel Inc fundamental analysis
No fundamental analysis for Nexgel Inc yet.
Nexgel Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nexgel Inc
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impai…
Full company profileNexgel Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nexgel Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.15M | 1.99M | 2.21M | 717K | 674K | 1.55M | 2.05M | 4.09M | 8.69M | 11.4M | 12.7M |
| Gross Profit | -114K | 147K | 514K | -137K | -291K | 8.00K | 256K | 374K | 2.75M | 4.51M | 4.34M |
| Operating Income | -1.86M | -969K | -1.89M | -1.92M | -2.26M | -2.57M | -3.35M | -3.48M | -3.55M | -3.35M | -6.93M |
| EBITDA | -1.54M | -653K | -1.57M | -1.86M | -2.20M | -2.20M | -3.11M | -2.73M | -2.90M | -2.12M | -2.11M |
| Net Income | -1.78M | -953K | -1.89M | -1.92M | -2.26M | -4.31M | -4.75M | -3.16M | -3.28M | -3.00M | -9.12M |
| EPS | -128 | -68 | -136 | -99 | -20 | -29 | -17 | -11 | -10 | -7.64 | -20 |
| Balance Sheet | |||||||||||
| Total Assets | 1.26M | 894K | 739K | 1.89M | 2.26M | 17.0M | 10.4M | 9.96M | 11.0M | 10.5M | 26.4M |
| Total Liabilities | 467K | 269K | 458K | 1.51M | 2.19M | 4.90M | 2.72M | 4.79M | 4.90M | 5.57M | 21.0M |
| Shareholders' Equity | 794K | 625K | 281K | 380K | 71.0K | 12.1M | 7.64M | 4.70M | 5.76M | 4.46M | 4.95M |
| Cash & Short-term Investments | - | - | 1.00 | 261K | 32.0K | 13.4M | 6.61M | 2.70M | 1.81M | 317K | 492K |
| Total Debt | - | - | - | 917K | 1.28M | 4.26M | 2.08M | 2.80M | 2.83M | 3.09M | 7.46M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.32M | -777K | -1.54M | -1.81M | -1.80M | -2.75M | -2.99M | -3.24M | -3.87M | -1.31M | -5.40M |
| Capital Expenditure | 0.00 | 7.00K | 312K | 312K | 312K | 269K | 96.0K | 696K | 443K | 68.0K | 170K |
| Free Cash Flow | -1.32M | -784K | -1.54M | -1.81M | -2.11M | -3.02M | -3.09M | -3.93M | -4.31M | -1.38M | -5.57M |
| Ratios | |||||||||||
| ROE | -223.7% | -152.5% | -671.9% | -506.1% | -3,188.7% | -35.7% | -62.1% | -67.2% | -57.0% | -67.3% | -184.4% |
| ROA | -140.8% | -106.6% | -255.5% | -101.7% | -100.3% | -25.4% | -45.8% | -31.7% | -29.9% | -28.7% | -34.5% |
| Net Profit Margin | -82.5% | -47.8% | -85.3% | -268.2% | -335.9% | -277.9% | -231.7% | -77.2% | -37.8% | -26.3% | -72.0% |
| Debt to Equity | - | - | - | 2.41x | 17.99x | 0.35x | 0.27x | 0.60x | 0.49x | 0.69x | 1.51x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nexgel Inc dividends
Nexgel Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Oct 12, 2026.
Who owns Nexgel Inc
- Insiders 12.74%
- Institutions 12.00%
- Public & others 75.26%
- Shares outstanding 536K
- Free float 384K
Top funds holding NXGL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 44.6K | 0.46% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 13.6K | 0.14% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 8.68K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 546.00 | 0.01% | 0.00% | Aug 2026 |
| DFA US Micro Cap I | 198.00 | 0.00% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap I | 152.00 | 0.00% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 144.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding NXGL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Susquehanna International Group, LLP | 85.1K | 0.87% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 79.1K | 0.81% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 71.9K | 0.74% | -44.09% | Jun 2026 |
| HRT FINANCIAL LLC | 69.5K | 0.71% | +348.41% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 55.0K | 0.56% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 48.9K | 0.50% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 41.0K | 0.42% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 34.0K | 0.35% | 0.00% | Jun 2026 |
| UBS Group AG | 24.7K | 0.25% | +272.85% | Jun 2026 |
| Jane Street Group LLC | 20.6K | 0.21% | -51.10% | Jun 2026 |
| State Street Corp | 17.3K | 0.18% | 0.00% | Jun 2026 |
| Northern Trust Corp | 13.4K | 0.14% | 0.00% | Jun 2026 |
| Hbk Sorce Advisory LLC | 12.5K | 0.13% | 0.00% | Jun 2026 |
| Ground Swell Capital, LLC | 11.2K | 0.11% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 2.16K | 0.02% | 0.00% | Jun 2026 |
| Citigroup Inc | 1.14K | 0.01% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 305.00 | 0.00% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 32.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 7.00 | 0.00% | 0.00% | Jun 2026 |
| FLAX POND CAPITAL, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Nexgel Inc company profile
- Company name
- Nexgel Inc
- Ticker
- NXGL.US
- Exchange
- USA Stocks
- Listed since
- Dec 22, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 19
- Fiscal year end
- December
- Address
- 2150 Cabot Boulevard West, Langhorne, PA, United States, 19047
- Phone
- 215 702 8550
- Website
- nexgel.com
About Nexgel Inc
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Nexgel Inc management
4- Mr. Brian J. Kieser CPAInterim CEO & Director · born 1967
- Mr. Ian Blackman CPAChief Financial Officer · born 1968
- Mr. Gregory J. RobbVice President of Operations
- Mr. Valter PintoManaging Director of KCSA Strategic Communications